Full text is available at the source.
Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: A systematic review and network meta-analysis
Effectiveness and safety of GLP-1 drugs for overweight or obese people with type 2 diabetes
AI simplified
Abstract
A total of 15,126 patients were analyzed across 41 randomized controlled trials evaluating Glucagon-like peptide-1 receptor agonists for type 2 diabetes with overweight/obesity.
- Tirzepatide was effective in lowering blood glucose levels compared to placebo, with a reduction in glycated hemoglobin of -1.64 and fasting blood glucose of -2.10.
- Patients experienced significant weight loss with Tirzepatide, showing a decrease in weight of -9.89 and a reduction in BMI of -3.85 compared to placebo.
- No widespread improvements were noted in lipid levels, blood pressure, or pancreatic function with GLP-1 receptor agonists.
- Adverse reactions were significant but overall deemed acceptable for GLP-1 receptor agonists.
- Conclusions about efficacy and safety should be interpreted cautiously due to limitations in the number and quality of studies.
AI simplified